ReviewTranslational pediatrics2015
Molecular genetic studies of complete hydatidiform moles.
Review in Translational pediatrics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 33 citations in OpenAlex.
- Dissecting trophoblastic heterogeneity in abnormal pregnancy: Insights from comparative analysis of twin-pregnancy with hydatidiform mole and coexisting live fetus.Genes & diseases · 2026Article
- Chromosome-specific epigenetic control and transmission of ribosomal DNA arrays in Hominidae genomes.Cell genomics · 2025Article
- Whole genome uniparental isodisomy detected using single nucleotide polymorphism (SNP) microarray in molar pregnancy: a case report.Molecular cytogenetics · 2025Article
- Overcoming challenges associated with broad sharing of human genomic data.Nature genetics · 2025Review
- Enhancing Clinical Applications by Evaluation of Sensitivity and Specificity in Whole Exome Sequencing.International journal of molecular sciences · 2024Article
- Epigenetic control and inheritance of rDNA arrays.bioRxiv : the preprint server for biology · 2024Article
- Gestational Trophoblastic Disease: Complete versus Partial Hydatidiform Moles.Diseases (Basel, Switzerland) · 2024Review
- Application of short tandem repeat (STR) genotyping in partial hydatidiform mole.American journal of translational research · 2023Article
- Hydatidiform Mole Presents As Pregnancy in a 48-Year-Old Perimenopausal Female: A Case Study.Cureus · 2022Article
- Epigenetic Dysregulation of Trophoblastic Gene Expression in Gestational Trophoblastic Disease.Biomedicines · 2021Article
- The Contribution of QF-PCR and Pathology Studies in the Diagnosis of Diandric Triploidy/Partial Mole.Diagnostics (Basel, Switzerland) · 2021Article
- Article
- NLRP7 is expressed in the ovine ovary and associated with in vitro pre-implantation embryo development.Reproduction (Cambridge, England) · 2019Article
- Dysregulation of Placental Functions and Immune Pathways in Complete Hydatidiform Moles.International journal of molecular sciences · 2019Article
- Recurrent complete hydatidiform mole: where we are, is there a safe gestational horizon? Opinion and mini-review.Journal of assisted reproduction and genetics · 2018Review
- Molecular and Immunohistochemical Characteristics of Complete Hydatidiform Moles.Balkan journal of medical genetics : BJMG · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Complete hydatidiform moles (CHM) are abnormal pregnancies with no fetal development resulting from having two paternal genomes with no maternal contribution. It is important to distinguish CHM from partial hydatidiform moles, and non-molar abortuses, due to the increased risk of gestational trophoblastic neoplasia. We evaluated a series of products of conception (POC) (n=643) investigated by genome-wide microarray comparative genomic hybridisation (CGH) with the aim of refining our strategy for the identification of complete moles. Among 32 suspected molar pregnancies investigated by STR genotyping to supplement microarray CGH testing, we found 31.3% (10/32) CHM; all identified among 3.6% (10/272) early first trimester POC. We suggest that when using microarray CGH that genotyping using targeted STR analysis should be performed for all POC referrals to aid in the identification of CHM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.